| |
|
HE | Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
|
|
| |
|
|
| |
| 3. | Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial) |
| |
BMJ Open Gastroenterol. 2020 Dec;7(1):e000531. doi: 10.1136/bmjgast-2020-000531.
K de Wit 1, J J Schaapman 2, F Nevens 3, J Verbeek 3, S Coenen 4, F J C Cuperus 5, M Kramer 6, E T T L Tjwa 7, N Mostafavi 8, M G W Dijkgraaf 9, O M van Delden 10, U H W Beuers 1, M J Coenraad 2, R B Takkenberg 11
|
|
| |
| 4. | The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis |
| |
J Hepatol. 2020 Dec 7;S0168-8278(20)33836-8. doi: 10.1016/j.jhep.2020.11.048.Online ahead of print.
Vicente Arroyo 1, Paolo Angeli 2, Richard Moreau 3, Rajiv Jalan 4, Joan Claria 5, Jonel Trebicka 6, Javier Fernández 5, Thierry Gustot 7, Paolo Caraceni 8, Mauro Bernardi 8, investigators from the EASL-CLIF Consortium, Grifols Chair; European Foundation for the Study of Chronic Liver Failure (EFClif)
|
|
| |
|
|
| |
| 6. | The use of Rifaximin in Patients with Cirrhosis |
| |
Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708. Online ahead of print.
Paolo Caraceni 1, Victor Vargas 2, Elsa Solà 3, Carlo Alessandria 4, Koos de Wit 5, Jonel Trebicka 6 7, Paolo Angeli 8, Rajeshwar P Mookerjee 9, François Durand 10, Elisa Pose 3, Aleksander Krag 11 12, Jasmohan S Bajaj 13, Ulrich Beuers 5, Pere Ginès 3
|
|
| |
|
|
| |
|
| |
|
|
|
|
|
